Advanced Research — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$615,269	267
2024	Research	$40,834	6
2023	Research	$10,025	4
2021	Research	$2,000	1

Breakdown

Who paid Research payments · program years 2021–2025

Regeneron Pharmaceuticals, Inc. $606,565 265 payments
Argenx US, Inc. $37,324 4 payments
E.R. Squibb & Sons, L.L.C. $15,343 5 payments
EyePoint Pharmaceuticals US, Inc. $6,250 1 payment
Alexion Pharmaceuticals, Inc. $2,000 1 payment
Celgene Corporation $646 2 payments

Studies the money was for Research payments · program years 2021–2025

A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) $600,166 263 payments
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease $37,324 4 payments
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 $7,016 1 payment
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration $6,399 2 payments
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis $6,250 1 payment
Phase III RRMM: 480Vd vs PVd (SUCCESSOR 1) - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH R $5,587 2 payments
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) $2,000 1 payment
Ph II/III RR LR MDS mono vs Placebo - A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG ) plus Best Supportive Care (BSC) versus Placebo $1,698 3 payments
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent $1,687 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.